Phase 1 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, both men and women
- People with a moderate level of heart failure symptoms, classified as NYHA functional class II or III (meaning symptoms appear during ordinary or minimal physical activity) (confirm with trial site)
- People whose heart pumps out less than 50% of blood with each beat, as measured by a heart scan
- People with a specific protein level in the blood (called NT-proBNP) above a certain threshold at the time of screening — the threshold differs depending on whether the person has a normal heart rhythm or a condition called atrial fibrillation (confirm with trial site)
- People who have been taking a heart failure medication called sacubitril/valsartan at a dose of at least 49/51 mg twice daily for at least 4 weeks before screening, with no recent dose changes
Who may not be able to join:
- People who had a serious worsening of heart failure requiring urgent treatment within the 3 months before screening
- People whose resting blood pressure (the top number) was below 105 mmHg at screening or at the start of the trial
- People who had a heart attack, stroke, mini-stroke, major heart or blood vessel surgery, or a procedure to open blocked arteries within the 6 months before screening
- People with significant problems with their heart valves (mitral or aortic), or anyone who has had a heart valve replacement — except where the mitral valve leak is caused by an enlarged heart
- People whose kidneys are functioning below a certain level, as measured by a specific blood test called eGFR (below 30 ml/min/1.73m²)
- People with a body mass index (a measure of body weight relative to height) above 40
- People currently taking certain medications, including strong inhibitors or inducers of a liver enzyme called CYP3A4, a drug called vericiguat, PDE5 inhibitors (a class of medication), or nitroglycerin-based products (confirm with trial site)
- Women who are able to become pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with Adverse Events (AEs); Number of participants with clinically significant changes in vital signs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.